MedTrace Logo

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

NCT03704688 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-05-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.

Conditions

  • Non Small Cell Lung Cancer
  • KRAS Gene Mutation

Interventions

DRUG

Trametinib 0.5 mg

0.5mg PO q daily

DRUG

Trametinib 1 MG

1.0 mg PO q daily

DRUG

Trametinib 1.5 MG

1.5mg PO q daily

DRUG

Trametinib 2 mg

2 mg PO q daily

DRUG

Ponatinib 15 MG

15mg PO q daily

DRUG

Ponatinib 30 MG

30mg PO q daily

Sponsors & Collaborators

Principal Investigators

  • Kathryn Arbour, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-09
Primary Completion
2022-02-04
Completion
2022-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03704688 on ClinicalTrials.gov